AscellaHealth Releases Q3 2024 Specialty & Rare Pipeline Digest™: FDA-Approved Biosimilars Outpaces Cell and Gene Therapy Amid Complex Regulatory Challenges

BERWYN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive digital resource of new, pending and upcoming specialty and rare disease drug launches, cell and gene therapies (CGTs) and biosimilars. This complimentary quarterly publication provides timely product updates to support the specialty drug market needs of stakeholders and decision-makers.

To read more, click here